176 related articles for article (PubMed ID: 10872030)
21. [Soon one "female distress" less. Irritable bowel syndrome responds to serotonin blockers].
MMW Fortschr Med; 2000 Sep; 142(37):55. PubMed ID: 11026224
[No Abstract] [Full Text] [Related]
22. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Avigan M; Justice R; Mackey AC; Nair N
Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
[No Abstract] [Full Text] [Related]
23. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
24. Alosetron approved for treatment of irritable bowel syndrome.
Miller JL
Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758
[No Abstract] [Full Text] [Related]
25. New drugs to treat irritable bowel syndrome being tested.
Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
[No Abstract] [Full Text] [Related]
26. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
Humphrey PP; Bountra C; Clayton N; Kozlowski K
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
[TBL] [Abstract][Full Text] [Related]
27. Innovative treatments for irritable bowel syndrome featured in new continuing ed program.
Rep Med Guidel Outcomes Res; 2000 Jul; 11(14):1-2, 5-6. PubMed ID: 11771560
[No Abstract] [Full Text] [Related]
28. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
[TBL] [Abstract][Full Text] [Related]
30. Neurotransmitter antagonism in management of irritable bowel syndrome.
Lembo T
Lancet; 2000 Mar; 355(9209):1030-1. PubMed ID: 10744083
[No Abstract] [Full Text] [Related]
31. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
[TBL] [Abstract][Full Text] [Related]
32. Novel medications for the irritable bowel syndrome: motility and sensation.
Camilleri M
J Pediatr Gastroenterol Nutr; 2001; 32 Suppl 1():S35-7. PubMed ID: 11321419
[No Abstract] [Full Text] [Related]
33. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
34. So what happened to alosetron?
Hyams JS
J Pediatr Gastroenterol Nutr; 2001 May; 32(5):513-4. PubMed ID: 11455947
[No Abstract] [Full Text] [Related]
35. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
36. Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
Whorwell PJ
Gut; 2001 May; 48(5):596-7. PubMed ID: 11302953
[No Abstract] [Full Text] [Related]
37. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
38. Alosetron and irritable bowel syndrome.
Mayer EA; Bradesi S
Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
[TBL] [Abstract][Full Text] [Related]
39. Drug therapy options for patients with irritable bowel syndrome.
Talley NJ
Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911
[TBL] [Abstract][Full Text] [Related]
40. Drug for irritable bowel syndrome taken off the market.
Charatan F
BMJ; 2000 Dec; 321(7274):1429. PubMed ID: 11228674
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
